Introduction: Adenoid cystic breast carcinoma is a tumour of extremely rare malignant behavior, belonging to the group of triple negative breast tumors but, unlike these, has a favorable prognosis with high survival if the diagnosis and management are appropriate [1,7,9]. Presentation of Case: A 34 year old female patient presented symptom is a well-circumscribed palpable mass in the right breast with recurrent breast pain that not improve with analgesic or progestin gel. Excision biopsy of a lump in the upper outer quadrant revealed adenoid cystic carcinoma. A right sided lumpectomy was performed, with sentinel node biopsy. Histopathology revealed a fibroadenoma accounting for one mass and adenoid cystic carcinoma in another, confirmed on Periodic acid Schiff (PAS) staining, with a very closely margin. A second lumpectomy was performed with focal adenoid cystic carcinoma. Finally a right side modified radical mastectomy (MRM) was performed. The sentinel node biopsy was negative. There was no evidence of recurrence or distant spread at follow-up 12 months postoperatively. Discussion: Adenoid cystic carcinoma of the breast is a rare tumor, of which very few cases have been described in the literature and which lacks in-depth studies on its diagnosis and management due to its rarity [1,2]. Nowadays, its diagnosis is based on biopsy excision and anatomopathological study. And the management, like the Basal_Like tumors of the breast, is based on surgical excision with a wide margin of safety. However, unlike these, axillary nodal study is not justified, and the use of posterior adjuvant is controversial with various opinions in this regard [1,3].

No abstract

Objective: to evaluate the effect of the combination of inositiol derivatives and lipid mediators on the metabolic and inflammatory profile of women with polycystic ovary syndrome.Material and Methods: Experimental, prospective and longitudinal study carried out in patients diagnosed with polycystic ovary syndrome (Rotterdam criteria) without treatment or previous dietary intervention. The following nutritional preparations were administered orally daily:• Group B: 4000 mg of myo -inositol + 30 mg of lipinovaThe metabolic profile is compared before and after 4 weeks of treatment in each patient, determining the insulin levels and the HOMA index. The inflammatory profile was analyzed by determining the levels of IL-6 before and after treatment. Results• 41 patients with polycystic ovary syndrome subdivided into 20 from group A and 21 from group B were studied.• Insulin levels before and after treatment were 17.9 +-9.3 SD and 10 +-4.09 SD, respectively, with statistically significant differences. •The HOMA index pre-treatment was 4.1 +-2.1 SD and 2.1+-1.1 SD post-treatment, with significant differences •The level of IL-6 was pretreatment was 3.8 +-1.5 Sd of 2.1 + -1.09 post treatment with significant differences Conclusion:The results of the study show the positive effect of the combined administration of inositolic derivatives and proresolution lipid mediators on the metabolic, clinical and inflammatory profile of patients with polycystic ovary syndrome.